Patent ID: 8609640

Claim:
A method for treating a B-RAF mutated melanoma in a subject, the method comprising: a) determining if the subject's melanoma carries a B-RAF mutation; and b) if the melanoma is determined to carry a B-RAF mutation, administering to the subject a composition comprising at least one compound of formula (I): wherein: R 1 is H R 2 is selected from the group consisting of H and trifluoromethylcarbonyl; or R 1 and R 2 are taken together with the core structure to form a heterocyclydiyl moiety of formula (a): R 3 is selected from the group consisting of —OR a and —NR b R c ; R a is a C 1-4 alkyl group optionally substituted with an imidazolyl; R b is selected from the group consisting of a C 1-4 alkyl group and a C 1-4 alkoxy group, wherein R b is substituted with 0, 1 or 2 groups each independently selected from the group consisting of —OCH 3 , —C(O)OH, —C(O)NR′R″, —NH(C 1-3 alkyl), —NH(CH 2 CH 2 O) n CH 3 , wherein n is 2-4, piperazinyl, N-methylpiperazinyl, piperidinyl, N-methylpiperidinyl, N-morpholinyl, imidazolyl, pyrrolidinyl, —OPO 3 H 2 and hydroxyl; wherein the —NH(C 1-3 alkyl) group is substituted with 0, 1 or 2 hydroxyl groups and wherein R′ and R″ are each independently selected from —H or —CH 3 ; and R c is H, or R b and R c are taken together with the nitrogen to which they are attached to form a heterocyclyl selected from the group consisting of formula (b) and formula (c): or a pharmaceutically acceptable salt thereof; in an amount effective for treating the B-RAF mutated melanoma.